 Novocure Ltd NASDAQ: NVCR has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields TTFields together with pembrolizumab and temozolomide for newly diagnosed glioblastoma GBM. Of the 19 patients with follow-up over nine months, the median progression-free survival was at least 11.2 months compared to 6.7 months from the historical control study EF-14, in which patients received TTFields and adjuvant temozolomide. 